Article

“3G” Trial: An RNA Editing Signature for Guiding Gastric Cancer Chemotherapy

2020-06-23

Abstract excerpt

<h4>Background & Aims</h4> Gastric cancer (GC) cases are often diagnosed at an advanced stage with poor prognosis. Platinum-based chemotherapy has been internationally accepted as first-line therapy for inoperable or metastatic GC. To achieve greater benefits, it is critical to select patients who are eligible for the treatment. Albeit gene expression profiling has been widely used as a genomic classifier to iden...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 893163fe-e12b-525a-ae56-ea493c86fed2
DOI: 10.1101/2020.06.22.164038

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

“3G” Trial: An RNA Editing Signature for Guiding Gastric Cancer ChemotherapyDOI 10.1101/2020.06.22.164038Read

Comprehensive Characterization of RNA Editing in Primary Gastric Adenocarcinoma through RNA-seq Data AnalysisSemantic proximity Read

Identification of A-to-I RNA editing profiles and their clinical relevance in lung adenocarcinoma.Semantic proximity Read

N6-methyladenosine demethylase FTO serves as an indicator for predicting prognosis and immunotherapy response in individuals with gastric cancerSemantic proximity Read

Identifying gastric cancer molecular subtypes by integrating DNA-based hierarchical classification strategy and clinical stratificationSemantic proximity Read

The RNA Editome of Esophageal Squamous Cell Carcinoma Identifies an ADAR1-CDK13 Editing Feedback Loop Mediating cGAS–STING Activation in Early TumorigenesisSemantic proximity Read

RNA Editing Dynamically Rewrites the Cancer Code.Semantic proximity Read

Adenosine-to-inosine RNA editing in cancer: molecular mechanisms and downstream targetsSemantic proximity Read

Development of a Novel Anoikis-Related Prognostic Signature and Validation of CD36 as a Potential Target for Reversing 5-FU Resistance in Gastric CancerSemantic proximity Read

N7-methylguanosine-based signature for tumor subtyping and prognosis and immunotherapy prediction of stomach cancerSemantic proximity Read

An integrated analysis of whole transcriptome and epigenome data reveals ENSR00000272060, an enhancer RNA, as a potential diagnostic biomarker in gastric cancerSemantic proximity Read

Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.Semantic proximity Read

Upregulated ONECUT2 impeded the efficacy of 5-FU treatment to relapsed patients and might be an emerging indicator of chemotherapy in gastric cancerSemantic proximity Read